» Articles » PMID: 19897178

Antipsychotic Dose Equivalents and Dose-years: a Standardized Method for Comparing Exposure to Different Drugs

Overview
Journal Biol Psychiatry
Publisher Elsevier
Specialty Psychiatry
Date 2009 Nov 10
PMID 19897178
Citations 467
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A standardized quantitative method for comparing dosages of different drugs is a useful tool for designing clinical trials and for examining the effects of long-term medication side effects such as tardive dyskinesia. Such a method requires establishing dose equivalents. An expert consensus group has published charts of equivalent doses for various antipsychotic medications for first- and second-generation medications. These charts were used in this study.

Methods: Regression was used to compare each drug in the experts' charts to chlorpromazine and haloperidol and to create formulas for each relationship. The formulas were solved for chlorpromazine 100 mg and haloperidol 2 mg to derive new chlorpromazine and haloperidol equivalents. The formulas were incorporated into our definition of dose-years such that 100 mg/day of chlorpromazine equivalent or 2 mg/day of haloperidol equivalent taken for 1 year is equal to one dose-year.

Results: All comparisons to chlorpromazine and haloperidol were highly linear with R(2) values greater than .9. A power transformation further improved linearity.

Conclusions: By deriving a unique formula that converts doses to chlorpromazine or haloperidol equivalents, we can compare otherwise dissimilar drugs. These equivalents can be multiplied by the time an individual has been on a given dose to derive a cumulative value measured in dose-years in the form of (chlorpromazine equivalent in mg) x (time on dose measured in years). After each dose has been converted to dose-years, the results can be summed to provide a cumulative quantitative measure of lifetime exposure.

Citing Articles

Dynamic functional connectivity patterns predict early antidepressant treatment response in drug-naïve, first-episode adolescent MDD.

Ran M, Zhang H, Jin M, Tao Y, Xu H, Zou S Front Neurosci. 2025; 19:1487754.

PMID: 39963258 PMC: 11830731. DOI: 10.3389/fnins.2025.1487754.


Energy of Functional Brain States Correlates With Cognition in Adolescent-Onset Schizophrenia and Healthy Persons.

Theis N, Bahuguna J, Rubin J, Banerjee S, Muldoon B, Prasad K Hum Brain Mapp. 2025; 46(1):e70129.

PMID: 39777939 PMC: 11707705. DOI: 10.1002/hbm.70129.


Cellular and extracellular white matter alterations after childhood trauma experience in individuals with schizophrenia.

Dauvermann M, Costello L, Tronchin G, Corley E, Holleran L, Mothersill D Psychol Med. 2025; :1-10.

PMID: 39757719 PMC: 11779554. DOI: 10.1017/S0033291724003064.


Increased Herpes simplex virus 1, Toxoplasma gondii and Cytomegalovirus antibody concentrations in severe mental illness.

Andreou D, Steen N, Jorgensen K, Ueland T, Wortinger L, Morch-Johnsen L Transl Psychiatry. 2024; 14(1):498.

PMID: 39695093 PMC: 11655861. DOI: 10.1038/s41398-024-03198-y.


Impact of Stress on the Endocannabinoid System: A [C]-CURB Positron Emission Tomography Study in Early Psychosis: Les effets du stress sur le système endocannabinoïde : étude par tomographie par émission de positons avec l'indicateur radioactif....

Weidenauer A, Garani R, Campos Oller P, Belen Blasco M, Rusjan P, Mizrahi R Can J Psychiatry. 2024; 70(3):251-259.

PMID: 39632555 PMC: 11622212. DOI: 10.1177/07067437241300958.


References
1.
Davis J, Chen N . Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004; 24(2):192-208. DOI: 10.1097/01.jcp.0000117422.05703.ae. View

2.
Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

3.
Small J, Hirsch S, Arvanitis L, Miller B, Link C . Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry. 1997; 54(6):549-57. DOI: 10.1001/archpsyc.1997.01830180067009. View

4.
Andreasen N, Flaum M, Arndt S . The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry. 1992; 49(8):615-23. DOI: 10.1001/archpsyc.1992.01820080023004. View

5.
Farde L, Wiesel F, Halldin C, Sedvall G . Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988; 45(1):71-6. DOI: 10.1001/archpsyc.1988.01800250087012. View